Incyte (INCY) Cash from Financing Activities (2010 - 2026)
Incyte (INCY) posted Cash from Financing Activities of $84.8 million for Q1 2026, down 38.42% on a QoQ basis from $137.7 million in Q4 2025, and up 769.15% year-over-year from $9.8 million in Q1 2025.
Incyte (INCY) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Incyte's Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $84.8 million for Q1 2026.
- Quarterly Cash from Financing Activities rose 769.15% year-over-year to $84.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $198.5 million (up 109.82% YoY) and the FY2025 annual result came in at $101.0 million, up 105.0% from the prior year.
- Cash from Financing Activities was $84.8 million for Q1 2026 at Incyte, down from $137.7 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $137.7 million in Q4 2025 and bottomed at -$2.0 billion in Q2 2024.
- A 5-year average of -$109.2 million and a median of -$2.5 million in 2022 frame the typical range for Cash from Financing Activities.
- Peak annual rise in Cash from Financing Activities reached 5794.22% in 2024, while the deepest fall reached 15620.49% in 2024.
- Incyte's Cash from Financing Activities stood at -$2.5 million in 2022, then surged by 113.95% to $346000.0 in 2023, then surged by 5794.22% to $20.4 million in 2024, then surged by 575.39% to $137.7 million in 2025, then tumbled by 38.42% to $84.8 million in 2026.
- Business Quant data shows INCY's Cash from Financing Activities at $84.8 million in Q1 2026, $137.7 million in Q4 2025, and -$12.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Incyte | 23.33 Bn | 19.32 Bn | 1.17 Bn | 84.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 84.82 Mn |
| Mar 31, 2026 | 84.82 Mn |
| Dec 31, 2025 | 137.74 Mn |
| Dec 31, 2025 | 137.74 Mn |
| Sep 30, 2025 | -12.78 Mn |
| Sep 30, 2025 | -12.78 Mn |
| Jun 30, 2025 | -11.25 Mn |
| Jun 30, 2025 | -11.25 Mn |
| Mar 31, 2025 | -12.68 Mn |
| Mar 31, 2025 | -12.68 Mn |
| Dec 31, 2024 | 20.39 Mn |
| Dec 31, 2024 | 20.39 Mn |
| Sep 30, 2024 | -32.35 Mn |
| Sep 30, 2024 | -32.35 Mn |
| Jun 30, 2024 | -2.00 Bn |
| Jun 30, 2024 | -2.00 Bn |
| Mar 31, 2024 | -12.41 Mn |
| Mar 31, 2024 | -12.41 Mn |
| Dec 31, 2023 | 346,000.00 |
| Dec 31, 2023 | 346,000.00 |